Bibliography
- Ruiz Cantero MT , Angeles Pardo M: European Medicines Agency policies for clinical trials leave women unprotected. J. Epidemiol. Community Health60 , 911–913 (2006).
- Murthy VH , KrumholzHM, GrossCP: Participation in cancer clinical trials: race-, sex-, and age-based disparities.JAMA291 , 2720–2726 (2004).
- Watson MA , GayL, StebbingsWS et al.: Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. Clin. Sci. (Lond.)104 , 537–545 (2003).
- Milano G , EtienneMC, Cassuto-ViguierE et al.: Influence of sex and age on fluorouracil clearance. J. Clin. Oncol.10 , 1171–1175 (1992).
- Etienne MC , LagrangeJL, DassonvilleO et al.: Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol.12 , 2248–2253 (1994).
- Hsiao HH , YangMY, ChangJG et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother. Pharmacol.53 , 445–451 (2004).
- Inoue S , HashiguchiM, ChiyodaT et al.: Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. Pharmacogenomics8 , 41–47 (2007).
- Gill S , LoprinziCL, SargentDJ et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol.22 , 1797–1806 (2004).
- Meta-Analysis Group In Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol.16 , 3537–3541 (1998).
- Stein BN , PetrelliNJ, DouglassHO et al.: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale Phase III trial. Cancer75 , 11–17 (1995).
- Tepper JE , O‘ConnellM, NiedzwieckiD et al.: Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114. J. Clin. Oncol.20 , 1744–1750 (2002).
- Singh S , ParulekarW, MurrayN et al.: Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J. Clin. Oncol.23 , 850–856 (2005).
- Mader RM , StegerGG, RizovskiB et al.: Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br. J. Clin. Pharmacol.40 , 209–215 (1995).
- Ulrich CM , RobienK, McLeodHL: Cancer pharmacogenetics: polymorphisms, pathways and beyond.Nat. Rev. Cancer3 , 912–920 (2003).
- Toffoli G , RussoA, InnocentiF et al.: Effect of methylenetetrahydrofolate reductase 677C>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer103 , 294–299 (2003).
- Cohen V , Panet-RaymondV, SabbaghianN et al.: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res.9 , 1611–1615 (2003).
- Vallbohmer D , BrabenderJ, YangDY et al.: Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin. Lung Cancer7 , 332–337 (2006).
- Innocenti F , UndeviaSD, IyerL et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol.22 , 1382–1388 (2004).
- Buckley DB , KlaassenCD: Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice.Drug Metab. Dispos.35 , 121–127 (2007).
- Dally H , EdlerL, JagerB et al.: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics13 , 607–618 (2003).
- Pao W , MillerVA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.J. Clin. Oncol.23 , 2556–2568 (2005).
- Fukuoka M , YanoS, GiacconeG et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol.21 , 2237–2246 (2003).
- Andre F , MazouniC, HortobagyiGN, PusztaiL: DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.Biochim. Biophys. Acta1766 , 197–204 (2006).
- Wang Y , JatkoeT, ZhangY et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes‘ B colon cancer. J. Clin. Oncol.22 , 1564–1571 (2004).